Hematology 2020 ASH Education Program: 62nd ASH® Annual Meeting and Exposition

Welcome to the 62nd annual meeting of the American Society of Hematology. This year’s congress is unique among ASH annual meetings—the first to be all-virtual and the first to be held in the midst of a raging pandemic. And just as the annual meeting has had to adapt to the circumstances, so too has Hematology 2020. For the first time, this year’s edition is electronic-only. Some of the chapters reference COVID-19 and its impact on hematologic disorders. Other new features include a new page design, visual abstracts, and shorter manuscripts with the aim of making Hematology more graphical. In spite of these changes, the essence of Hematology remains the same. As always, you can count on high quality content spanning the breadth of malignant and nonmalignant hematology, based on a state-of-the-art Education Program prepared by this year’s Education Co-Chairs, Dr. Sioban Keel and Dr. Christopher Flowers. Dr. Andrew Roberts will deliver the Ham-Wasserman Lecture on Therapeutic Development and Current Uses of BCL-2 Inhibition, and his article is also included. This volume is the culmination of the efforts of many individuals and their selfless commitment to ASH, including the authors, reviewers, designer (Debra Naylor), and ASH staff (Michelle Lee, Kenneth April, and Brian Cannon). In these difficult times, we hope that you find Hematology to be the valued resource that it has always strived to be: a means of helping you keep current with the torrid pace of progress in hematology by highlighting recent practice-changing clinical advances as well as putting cutting edge basic advances into clinical context. Happy reading, and please stay safe. Front Cover Contents Editors’ Message Reviewers Continuing Medical Education Information Ham-Wasserman Lecture Therapeutic development and current uses of BCL-2 inhibition A Map for the Changing Landscape of CLL Approaches for relapsed CLL after chemotherapy-free frontline regimens Chemotherapy-free frontline therapy for CLL:is it worth it? Standard treatment approaches for relapsed/refractory CLL after frontline chemoimmunotherapy Treatment of relapsed CLL after venetoclax Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide? Does patient fitness play a role in determining first-line treatment of AML? How to approach shared decision making when determining consolidation, maintenance therapy,and transplantation in AML Management of toxicities associated with targeted therapies for AML: when to pushthrough and when to stop Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, andplatelet disorders Laboratory surveillance of immune-mediated TTP Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time? Can we use epigenetics to prime chemoresistant lymphomas? Harnessing lymphoma epigenetics to improve therapies Novel targets in aggressive lymphoma Beyond the Marrow Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes Extrahematopoietic manifestations of the short telomere syndromes Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer? Optimizing management of acute leukemia in community centers and when to refer Practice patterns and outcomes for adults with AML receiving care in community vs academic settings AML—So Many Treatment Options; How Do You Decide? Approaches to aggressive B-cell lymphomas in less fit patients Challenging Situations for Patients with Aggressive Lymphomas Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas Strategies for aggressive T-cell lymphoma: divide and conquer Chronic Transfusion Support: Challenging Cases Challenges in chronic transfusion for patients with thalassemia Outpatient transfusions for MDS Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time? Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism? When I treat a patient with acute pulmonary embolism at home Which patients are at high risk of recurrent venous thromboembolism (DVT and PE)? Advanced therapies and extracorporealmembrane oxygenation for the management of high-risk pulmonary embolism Genetic Testing for Heritable Hematologic Disorders Informed consent for genetic testingin hematology Identifying potential germline variants from sequencing hematopoietic malignancies Handling Challenging Questions in the Management of CML First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase CML? How to manage CML patients with comorbidities Handling challenging questions in themanagement of CML:when is it safe to stop tyrosine kinase inhibitors? Immunotherapy in Multiple Myeloma Sequencing multiple myeloma therapies with and after antibody therapies Bispecifics, trispecifics, and other novel immune treatments in myeloma Future of CAR T cells in multiple myeloma Should all newly diagnosed MM patients receive CD38 antibody–based treatment? Improving Symptom Control for Children with Hematological Malignancies Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies Indolent Lymphomas: Answers to Smoldering Questions How do I sequence therapy for follicular lymphoma? How do we sequence therapy for marginal zone lymphomas? Transformed lymphoma: what should I do now? Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases Preventing infections in children and adults with asplenia Managing Toxicities of Targeted Therapies in CLL Managing toxicities of Bruton tyrosine kinase inhibitors Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of CLL Management of AL amyloidosis in 2020 Monoclonal Gammopathies of Determined Significance Management of Waldenstr ̈om macroglobulinemia in 2020 Monoclonal gammopathies of clinical significance More Anxiety-Provoking Hematology Consults A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP Myelodysplastic Syndromes: What We Have and What We Want Existing agents, novel agents, or transplantation for high-risk MDS Patient stratification in MDS: how a puzzle may become a map Therapy for lower-risk MDS Myeloproliferative Disorders: Too Many Cells, Too Few Therapies Applied genomics in MPN presentation Genomics of MPN progression Genomics of MDS/MPN overlap syndromes MDS/MPN overlap syndromes: a focused review Out of Balance: Anemias Due to Disordered Iron Homeostasis Inherited microcytic anemias Global look at nutritional and functional iron deficiency in infancy Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick? Pediatric Hematological Malignancies: CARs for Kids Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma CAR T cells for other pediatric non–B-cell hematologic malignancies CAR T cells vs allogeneic HSCT for poor-risk ALL What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell ALL? Platelet Transfusions for Hematology/Oncology Patients Does ABO and RhD matching matter for platelettransfusion? How well do platelets prevent bleeding? Platelet transfusion refractoriness: how do I diagnose and manage? The use of premedications for platelet transfusions in pediatric patients Selected Hemostasis and Thrombosis Topics in Women Management of heavy menstrual bleeding on anticoagulation Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management Women and bleeding disorders: diagnostic challenges Abnormal uterine bleeding in users of rivaroxaban and apixaban The Brain and Pain in Sickle Cell Disease Neuropathic pain in sickle cell disease: measurement and management Optimizing the management of chronic pain in sickle cell disease The Emerging Role of Targeted Therapies and Cell Therapy in Transplant Next-generation cell therapies: theemergingrole of CAR-NK cells Practical aspects of building a new immunotherapy program: the future of cell therapy Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma Fundamentals of immunology for understanding immunotherapy for lymphoma Immunotherapy with cells Immunotherapy with drugs Nonanticoagulant Interventions in Venous Thromboembolism Role of venous stenting for venous thromboembolism Thrombolytic therapy in acute venous thromboembolism Inferior vena cava filters: a framework for evidence-based use Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism? What Hematologists Need to Know About Giving and Stopping Aspirin Does aspirin prevent venous thromboembolism? Combining antiplatelet and anticoagulant therapy in cardiovascular disease Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology Allogeneic HSCT in adults with primary immunodeficiency How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs) Erratum Blank Page